Cargando…

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis

BACKGROUND: As new therapies emerge which increase the risk of autoimmune disease it is increasingly important to understand the incidence of autoimmune disease in multiple sclerosis (MS). OBJECTIVE: The purpose of this review is to estimate the incidence and prevalence of comorbid autoimmune diseas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marrie, Ruth Ann, Reider, Nadia, Cohen, Jeffrey, Stuve, Olaf, Sorensen, Per S, Cutter, Gary, Reingold, Stephen C, Trojano, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429166/ https://www.ncbi.nlm.nih.gov/pubmed/25533299 http://dx.doi.org/10.1177/1352458514564490

Ejemplares similares

The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of cancer in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Recommendations for observational studies of comorbidity in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment
por: Cohen, Jeffrey A, et al.
Publicado: (2019)

The challenge of comorbidity in clinical trials for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

Clinical trials in multiple sclerosis: milestones
por: Zhang, Yinan, et al.
Publicado: (2018)

Evolution of clinical trials in multiple sclerosis
por: Zhang, Yinan, et al.
Publicado: (2019)

Uptake and Attitudes About Immunizations in People With Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Attitudes of people with multiple sclerosis toward brain donation
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Preferred Sources of Health Information in Persons With Multiple Sclerosis: Degree of Trust and Information Sought
por: Marrie, Ruth Ann, et al.
Publicado: (2013)

Health Literacy Association With Health Behaviors and Health Care Utilization in Multiple Sclerosis: A Cross-Sectional Study
por: Marrie, Ruth Ann, et al.
Publicado: (2014)

Disease-modifying therapy prescription patterns in people with multiple sclerosis by age
por: Zhang, Yinan, et al.
Publicado: (2021)

Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2019)

Physical and Mental Health–Related Quality of Life Trajectories Among People With Multiple Sclerosis
por: O'Mahony, Julia, et al.
Publicado: (2022)

Incidence and prevalence of multiple sclerosis in Europe: a systematic review
por: Kingwell, Elaine, et al.
Publicado: (2013)

Severity and worsening of fatigue among individuals with multiple sclerosis
por: Salter, Amber, et al.
Publicado: (2023)

Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis
por: Girolamo, Francesco, et al.
Publicado: (2014)

The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives
por: Hussain, Rehana Z, et al.
Publicado: (2022)

Clinical trials in multiple sclerosis: potential future trial designs
por: Manouchehri, Navid, et al.
Publicado: (2019)

Sources of Cannabis Information and Medical Guidance for Neurologic Use: NARCOMS Survey of People Living With Multiple Sclerosis
por: Salter, Amber, et al.
Publicado: (2022)

Pregnancy, sex and hormonal factors in multiple sclerosis
por: Miller, David H, et al.
Publicado: (2014)

Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region
por: Hittle, Michael, et al.
Publicado: (2023)

A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod
por: Salter, Amber, et al.
Publicado: (2021)

High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis
por: Rotstein, Dalia, et al.
Publicado: (2021)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

The Barancik lecture: Comorbidity in multiple sclerosis—Looking backward, looking forward
por: Marrie, Ruth Ann
Publicado: (2023)

The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry
por: Nickerson, Molly, et al.
Publicado: (2013)

Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
por: Zhang, Yinan, et al.
Publicado: (2020)

The role of the complement system in Multiple Sclerosis: A review
por: Saez-Calveras, Nil, et al.
Publicado: (2022)

Defining the clinical course of multiple sclerosis: The 2013 revisions
por: Lublin, Fred D., et al.
Publicado: (2014)

The Prevalence of Multiple Sclerosis in 3 US Communities
por: Williamson, Dhelia M., et al.
Publicado: (2009)

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
por: Forsthuber, Thomas G., et al.
Publicado: (2016)

The Prevalence of Multiple Sclerosis in 3 US Communities: The Role of Vitamin D [Response to Letter]
por: Noonan, Curtis W., et al.
Publicado: (2010)

National estimates of self-reported sitting time in adults with multiple sclerosis
por: Sasaki, JE, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g0mj1du16dkg9ijd78q9tb3blf